ECTRIMS 2022 | Clinical implementation of including optical nerve lesions in MS diagnostic criteria

Angela Vidal-Jordana, MD, PhD, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d’Hebron University Hospital, Barcelona, Spain, explains some of the necessary steps to implement the inclusion of optical nerve lesions in multiple sclerosis (MS) diagnosis. Firstly, the observed optic neuropathy must be able to be confirmed as optic neuritis i.e., due to inflammation. Secondly, the optic neuritis must be confirmed as due to MS and not due to another demyelinating disease such as myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Guidelines on which diagnostic tests to use in these circumstances would be needed as well, given that not all tests demonstrate the same sensitivity and that some tests may be more useful than others at different stages in the disease course. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.